# Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

> **NCT02001623** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 195 (actual)

## Conditions studied

- Ovary Cancer
- Cervix Cancer
- Endometrium Cancer
- Bladder Cancer
- Prostate Cancer (CRPC)
- Esophagus Cancer
- Lung Cancer(NSCLC)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)

## Interventions

- **DRUG:** Tisotumab Vedotin (HuMax-TF-ADC)

## Key facts

- **NCT ID:** NCT02001623
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-30
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2021-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001623, "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02001623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*